Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

Jeffery J. Auletta, Monzr M. Al Malki, Todd DeFor, Brian C. Shaffer, Mahasweta Gooptu, Javier Bolanos-Meade, Ramzi Abboud, Adrienne D. Briggs, Farhad Khimani, Dipenkumar Modi, Richard Newcomb, Elizabeth J. Shpall, Caitrin Bupp, Stephen R. Spellman, Heather E. Stefanski, Antonio M. Jimenez Jimenez, Steven M. Devine

Blood (2023) 142 (Supplement 1): 780.

https://doi.org/10.1182/blood-2023-172722

Published: 2023

Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 613.

https://doi.org/10.1182/blood-2023-174209

Published: 2023

Journal Articles

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Muhit Ozcan, Fangfang Lv, Lalita Norasetthada, Ewa Paszkiewicz-Kozik, Joaquin Díaz Schmidt, Dipenkumar Modi, Alexander Fosså, Sagun Goyal, Won Seog Kim, Seung Tae Lee, Armando Santoro, Mehmet Sonmez, Kumudu Pathiraja, Nishitha Reddy, Patricia Marinello, Yuqin Song

Blood (2023) 142 (Supplement 1): 1720.

https://doi.org/10.1182/blood-2023-186788

Published: 2023

Journal Articles

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Blood (2023) 142 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2023-188545

Published: 2023

Journal Articles

Acute Leukemia and MDS Patients Older Than 70 Years Have Inferior Survival Following Allogeneic Stem Cell Transplant Compared to Those with 60-69 Years of Age

Asmita Shukla, Seongho Kim, Hyejeong Jang, Andrew Kin, Aasiya Matin, Lois Ayash, Abhinav Deol, Voravit Ratanatharathorn, Joseph Uberti, Dipenkumar Modi

Blood (2023) 142 (Supplement 1): 3612.

https://doi.org/10.1182/blood-2023-190562

Published: 2023

Journal Articles

HLA-Haploidentical Vs Mismatched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis for AML and MDS: Is There a Winner?

Dipenkumar Modi, Maya Shatta, Seongho Kim, Abhinav Deol, Andrew Kin, Asif Alavi, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti

Blood (2022) 140 (Supplement 1): 694–695.

https://doi.org/10.1182/blood-2022-166536

Published: 2022

Journal Articles

Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients

Muthu Veeraputhiran, Amitkumar Mehta, Alvaro J. Alencar, Dipenkumar Modi, Timothy J. Voorhees, Mayur Narkhede

Blood (2022) 140 (Supplement 1): 12089–12091.

https://doi.org/10.1182/blood-2022-158595

Published: 2022

Journal Articles

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Blood (2022) 140 (Supplement 1): 9390–9392.

https://doi.org/10.1182/blood-2022-159001

Published: 2022

Journal Articles

Does Choice of Salvage Regimen Impact Stem Cell Mobilization in Hodgkin's Lymphoma?

Abdul Moiz Khan, Neha Venkatesh, Joseph P. Uberti, Voravit Ratanatharathorn, Dipenkumar Modi, Lois Ayash, Asif Alavi, Andrew Kin, Aasiya Matin, Abhinav Deol

Blood (2022) 140 (Supplement 1): 7565–7566.

https://doi.org/10.1182/blood-2022-164618

Published: 2022

Journal Articles

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Blood (2022) 139 (10): 1452–1468.

https://doi.org/10.1182/blood.2021013443

Published: 2022

Includes: Supplemental data

Journal Articles

Incidence, Risk Factors and Outcomes of Pancytopenia Following Chimeric Antigen Receptor (CAR)-T Cell Therapy in Relapsed Refractory Diffuse Large B Cell Lymphoma

Malini Surapaneni, Samer Alkassis, Seongho Kim, Abhinav Deol, Lois Ayash, Asif Alavi, Andrew Kin, Voravit Ratanatharathorn, Joseph P. Uberti, Dipenkumar Modi

Blood (2021) 138 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2021-148961

Published: 2021

Journal Articles

Feasibility of Outpatient CAR T Cell Therapy: Experience of a Single Institution

Yusra F Shao, Dipenkumar Modi, Andrew Kin, Asif Alavi, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti, Abhinav Deol

Blood (2021) 138 (Supplement 1): 4828.

https://doi.org/10.1182/blood-2021-146283

Published: 2021

Journal Articles

Phase 1/2 Study of Nexi-001 Donor-Derived Multi-Antigen Specific CD8+ T Cells for the Treatment of Relapsed Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Transplantation

Monzr M. Al Malki, Sumithira Vasu, Dipenkumar Modi, Miguel-Angel Perales, Lucy Y Ghoda, Donna Bui, Vineetha Edavana, Emily Lu, Sojung Kim, Lauren Suarez, Mathias Oelke, Daniel Bednarik, Robert D Knight, Juan C. Varela

Blood (2021) 138 (Supplement 1): 4819.

https://doi.org/10.1182/blood-2021-152419

Published: 2021

Journal Articles

Outcome of Severe Aplastic Anemia Post Allogenic Stem Cell Transplant with Mycophenolate and Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis

Omar Albanyan, Hyejeong Jang, Seongho Kim, Andrew Kin, Asif Alavi, Lois Ayash, Voravit Ratanatharathorn, Dipenkumar Modi, Joseph P. Uberti, Abhinav Deol

Blood (2021) 138 (Supplement 1): 4879.

https://doi.org/10.1182/blood-2021-144995

Published: 2021

Journal Articles

A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with Previously Untreated Double and Triple Hit Lymphoma

Dipenkumar Modi, Seongho Kim, Silva Pregja, Christiane Houde, Kathy A. Reichel, Rod Ramchandren

Blood (2021) 138 (Supplement 1): 3561.

https://doi.org/10.1182/blood-2021-149793

Published: 2021

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

Impact of Pre-Transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission

Omar Albanyan, MD, Samer Alkassis, Seongho Kim, PhD, Andrew Kin, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Dipenkumar Modi, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140079

Published: 2020

Journal Articles

Incidence, Risk Factors and Outcomes of Cardiac Toxicity in Haploidentical Peripheral Stem Cell Transplantation with High Dose Cyclophosphamide

Omar Albanyan, MD, Seongho Kim, PhD, Anupama Kottam, MD, Abhinav Deol, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Dipenkumar Modi, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141416

Published: 2020

Journal Articles

Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+ T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses

Monzr M. Al Malki, MD, Miguel-Angel Perales, MD, Dipenkumar Modi, MD, Sumithira Vasu, MDMBBS, Megan Nelson, RN, Donna Bui, Sojung Kim, Ruipeng Wang, Emily Lu, Mathias Oelke, Han Myint, MDFRCPath,FRCP, Juan C. Varela, MDPhD

Blood (2020) 136 (Supplement 1): 31–33.

https://doi.org/10.1182/blood-2020-139342

Published: 2020

Journal Articles

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-137221

Published: 2020

NARROW

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Acute Leukemia and MDS Patients Older Than 70 Years Have Inferior Survival Following Allogeneic Stem Cell Transplant Compared to Those with 60-69 Years of Age

HLA-Haploidentical Vs Mismatched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis for AML and MDS: Is There a Winner?

Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Does Choice of Salvage Regimen Impact Stem Cell Mobilization in Hodgkin's Lymphoma?

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Incidence, Risk Factors and Outcomes of Pancytopenia Following Chimeric Antigen Receptor (CAR)-T Cell Therapy in Relapsed Refractory Diffuse Large B Cell Lymphoma

Feasibility of Outpatient CAR T Cell Therapy: Experience of a Single Institution

Phase 1/2 Study of Nexi-001 Donor-Derived Multi-Antigen Specific CD8+ T Cells for the Treatment of Relapsed Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Transplantation

Outcome of Severe Aplastic Anemia Post Allogenic Stem Cell Transplant with Mycophenolate and Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis

A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with Previously Untreated Double and Triple Hit Lymphoma

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Impact of Pre-Transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission

Incidence, Risk Factors and Outcomes of Cardiac Toxicity in Haploidentical Peripheral Stem Cell Transplantation with High Dose Cyclophosphamide

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only